9 completed. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 1 | Completed 1 |
Follow asunaprevir: new trials by email Literature Review of asunaprevir trials Research Report on asunaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir Daclatasvir, Asunaprevir - Hepatitis C Infection | Phase 1 | Completed | Bristol-Myers Squibb | 88 | 2014-12-01 | 2015-02-24 |
| Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin Daclatasvir, Asunaprevir and BMS-791325 FDC, BMS-791325, Rosuvastatin - Hepatitis C | Phase 1 | Completed | Bristol-Myers Squibb | 18 | 2014-04-01 | 2014-07-18 |
| To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet DCV 3DAA FDC, BMS-791325 - Hepatitis C | Phase 1 | Completed | Bristol-Myers Squibb | 41 | 2014-04-01 | 2014-07-10 |
| Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 FDC of Daclatasvir, Asunaprevir and BMS-791325, FDC of Norethindrone and Ethinyl Estradiol, BMS-791325 - Hepatitis C | Phase 1 | Completed | Bristol-Myers Squibb | 20 | 2014-04-01 | 2014-08-15 |
| Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease Asunaprevir - Hepatitis C | Phase 1 | Completed | Bristol-Myers Squibb | 48 | 2012-11-01 | 2013-11-11 |
| Drug Interaction Oral Contraceptive Pill (OCP) Ortho Tri-Cyclen®, BMS-650032 - Hepatitis C Virus | Phase 1 | Completed | Bristol-Myers Squibb | 20 | 2010-01-01 | 2011-01-25 |
| Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032 BMS-650032 - Hepatic Insufficiency | Phase 1 | Completed | Bristol-Myers Squibb | 28 | 2009-12-01 | 2011-10-26 |
| Drug-Drug Interaction Study in Healthy Subjects BMS-650032, BMS-790052 - Hepatitis C | Phase 1 | Completed | Bristol-Myers Squibb | 28 | 2009-05-01 | 2011-01-07 |
| A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects BMS-650032 or Placebo - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 24 | 2008-01-01 | 2010-09-13 |
Hepatitis C (7) · Hepatic Insufficiency (1) · Hepatitis C, Chronic (1)
United States (6)
Rebecca N Wood-Horrall, MD (1)